|
Patients With Severe Acute Exacerbation of COPD Ans Admitted in ICU Register.
RECRUITINGSponsored by Alexis FERRE
Actively Recruiting
SponsorAlexis FERRE
Started2022-10-01
Est. completion2027-10-01
Eligibility
Age40 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT06257329
Summary
The objective of this prospective observational study is to describe the epidemiological, clinical and biological characteristics of admitted patients in ICU for severe acute exacerbation of COPD, to assess the different therapeutics used, to evaluate the prognosis of patients with short, medium and long term ( 1 year) and the various factors associated with survival in ICU
Eligibility
Age: 40 Years+Healthy volunteers accepted
Inclusion Criteria: 1. Age ≥ 40 years old 2. COPD documented or strongly suspected * Chronic respiratory symptoms (dyspnoea, cough and/or sputum) * Exposure to a known risk factor for COPD (such as tobacco smoke) * If available, respiratory function tests showing non- or partially reversible obstructive syndrom (post-bronchodilator ratio FEV1/CV \< 0.7) 3. Severe acute exacerbation, defined as a worsening of the patient's usual respiratory symptoms with signs of acute respiratory distress (polypnoea ≥ 30 cycles.min-1 or use of accessory respiratory muscles) and/or hypercapnic acidosis (with PaCO2 ≥ 45 mmHg and pH ≤ 7.35) 4. Admission to an ICU, a step-up unit or a respiratory care unit Exclusion Criteria: 1. Known asthma (according to the criteria of the international "Global initiative for asthma" guidelines) 2. Patient refusal to participate (information note, application for non-opposition)
Conditions2
COPDCOPD Exacerbation
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
SponsorAlexis FERRE
Started2022-10-01
Est. completion2027-10-01
Eligibility
Age40 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT06257329